Mesenchymal Stromal Cells to Treat Steroid-refractory Graft Versus Host Disease after Bone Marrow Transplantatio

Phase 1

Completed

• Conditions: Graft Versus Host Disease; Inflammatory and Immune System - Other inflammatory or immune system disorders; Blood - Haematological diseases

• Registration Number: ACTRN12610000068066
• Lead Sponsor: R.P.Herrmann

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-01-20
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Age 18-60
Steroid-refractory graft versus host disease post allogeneic haemopoietic stem cell transplant
Informed consent given

Exclusion Criteria

No informed consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Safety assessed clinically and by blood tests<br>weekly for 4 weeks, then monthly for 12 months after therapy[12 months after therapy finished, as assessed weekly for 4 weeks after therapy finished, then monthly to 12 months]

Secondary Outcome Measures

Name	Time	Method
Overall Survival as measured by actuarial survival from data linkage to medical records[12 months following completion of mesenchymal stromal cell therapy]